Evaluation of the effectiveness of Curcumin in the improving patients with autoimmune hepatitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221112056476N1

Enrollment

Registered

2024-03-06

Start date

2024-03-10

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune hepatitis. Autoimmune hepatitis

Interventions

Intervention 1: Intervention group: Patients with standard autoimmune hepatitis treatment protocol with 500 mg per day of curcumin for 2 months. Intervention 2: Control group: Patients with standard a

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age range from 18 to 50 years Suffering from autoimmune hepatitis based on diagnostic criteria (abnormalities of AST and ALT levels, hypergammaglobulinemia and increased serum IgG levels), positive serological findings (SMA, ANA and anti-LKM1) and histological findings and confirmed by an adult gastroenterologist

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Complete Blood Count (CBC). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Blood cells count.;Bilirubin (Bill). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Antinuclear antibody. Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: ELISA.;Alanine Transaminase (ALT). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Alkaline Phosphatase (ALP). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Aspartate Aminotransferase (AST). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Immunoglobulin G (IgG). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: ELISA.	—

Measure

Time frame

Complete Blood Count (CBC). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Blood cells count.;Bilirubin (Bill). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Antinuclear antibody. Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: ELISA.;Alanine Transaminase (ALT). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Alkaline Phosphatase (ALP). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Aspartate Aminotransferase (AST). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: Based on laboratory tests.;Immunoglobulin G (IgG). Timepoint: Before curcumin consumption and 2 months after curcumin consumption. Method of measurement: ELISA.

—

Secondary

Measure	Time frame
Response to treatment. Timepoint: 2 months after consumption the Curcumin. Method of measurement: Based on the normalization of Aminotransferases and Gammaglobin levels less than UMN.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Shahraki

Zahedan University of Medical Sciences

shahrakis@zaums.ac.ir+98 915 340 9110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026